BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 10797826)

  • 1. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
    Jourdan E; Richard B
    Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
    Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
    Molina A
    Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.
    Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S
    Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.
    Motta G; Cea M; Moran E; Carbone F; Augusti V; Patrone F; Nencioni A
    Clin Dev Immunol; 2010; 2010():428253. PubMed ID: 21437222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
    Maloney DG; Press OW
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
    Wood AM
    Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment approaches to indolent non-Hodgkin's lymphoma.
    Seymour JF
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Auto-immune manifestations in Non-Hodgkin's lymphoma].
    Jardin F; Lévesque H; Tilly H
    Rev Med Interne; 2005 Jul; 26(7):557-71. PubMed ID: 15996570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
    Feuring-Buske M; Buske C; Unterhalt M; Hiddemann W
    Ann Hematol; 2000 Apr; 79(4):167-74. PubMed ID: 10834503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
    Maloney DG
    J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab].
    Okamoto R; Maeda Y; Sasaki T
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.